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Abstract
Background
International collaborative research is a mechanism for improving the development of dis-
ease-specific therapies and for improving health at the population level. However, limited
data are available to assess the trends in research output related to orphan diseases.
Methods and Findings
We used bibliometric mapping and clustering methods to illustrate the level of fragmentation
in myeloma research and the development of collaborative efforts. Publication data from
Thomson Reuters Web of Science were retrieved for 2005–2009 and followed until 2013.
We created a database of multiple myeloma publications, and we analysed impact and co-
authorship density to identify scientific collaborations, developments, and international key
players over time. The global annual publication volume for studies on multiple myeloma in-
creased from 1,144 in 2005 to 1,628 in 2009, which represents a 43% increase. This in-
crease is high compared to the 24% and 14% increases observed for lymphoma and
leukaemia. The major proportion (>90% of publications) was from the US and EU over the
study period. The output and impact in terms of citations, identified several successful
groups with a large number of intra-cluster collaborations in the US and EU. The US-based
myeloma clusters clearly stand out as the most productive and highly cited, and the Europe-
an Myeloma Network members exhibited a doubling of collaborative publications from 2005
to 2009, still increasing up to 2013.
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Conclusion and Perspective
Multiple myeloma research output has increased substantially in the past decade. The frag-
mented European myeloma research activities based on national or regional groups are
progressing, but they require a broad range of targeted research investments to improve
multiple myeloma health care.
Introduction
Multiple myeloma is an orphan malignant disorder of plasma cells. The incidence of multiple
myeloma is 5–6 cases per 100,000 inhabitants. Knowledge of the essential pathogenic mecha-
nisms and therapeutic possibilities has increased substantially over the last decade. In parallel,
a broad range of novel technologies has resulted in new diagnostic, prognostic, and
predictive procedures.
To exploit the clinical benefits of these recent developments, international collaborations
have been organised through the European Myeloma Network (EMN), which was founded
and legalised in 2003 by leading research groups. EMN is a Pan-European umbrella organisa-
tion that unites basic and clinical research groups. It provides a directory for these groups to
pursue specific research and clinical goals together [1, 2].
The primary achievement of the EMN to date has been to introduce uniform criteria
for diagnostic and prognostic assays in multiple myeloma. This has been accomplished
through workshops focused on specific procedures related to biobanking, interphase FISH,
multiparametric flow cytometry, and microarray technologies [3, 4]. The EMN has established
two major working groups. The first is the “Biology Group”, which serves as an intermediary
for the exchange of diagnostic tools and tumour samples [5–7]. The second group is the “Clini-
cal Trial Group” which, in addition to publishing recommendations [8–12], has organised in-
ternational collaborative clinical phase II and III trials supported by
pharmaceutical companies.
The EMN is currently recognised internationally as a key promoter of interactions between
researchers, companies, patient groups, and individuals working in different areas of the grow-
ing myeloma field. Therefore, the EMN provides a “golden opportunity” for continuing work
on multiple myeloma and for preparing a strategy to support translation of basic discoveries
into the clinic. In our aim to create an ideal future set-up for the EMN vision, we have used bib-
liometric mapping and cluster models to address questions related to the previous fragmenta-
tion of EU myeloma research. Our goals were to identify collaborative groups and to evaluate
their outcomes and development over time. Finally, we relate our findings to other research
fields with higher productivity, like lymphoma and leukaemia.
The findings of this study will allow us to restructure the EMN organisation and manage-
ment, based on a strategy with focus on work that has high impact on individualized medicine.
Implementation of individualized medicines has been limited but recent policy in EU has ad-
dressed central issues including biomarker validation, biobanking, clinical trials, data handling,
public-private innovative medicines initiative and funding to personalized medicine. Initia-
tives, which future EMN work needs to take into consideration to speed up drug development
and treatment strategies.
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Materials and Methods
Analytic strategy
All bibliometric data were extracted from the Science Citation Index-Expanded (SCI-E) from
Thomson Reuters Web of Science (WoS). The extraction was performed with topic queries for
haematological malignancies, including multiple myeloma, lymphoma, and leukaemia. SCI-E
is considered one of the largest citation databases in the world; it contains information on
paper citation frequency and bibliographic metadata. Thus, it provides information that may
not be retrieved from more specialised medical databases, such as PubMed MEDLINE or
EMBASE. Citations to a paper can be used as a proxy for the impact a report has made on the
research community, and therefore, the citation frequency can serve as an indicator of the im-
portance, quality, or usefulness of the information [13].
Research papers on the disease areas of interest published during the years 2005–09 were
identified as shown in S1 Table. This list was compared to results from similar queries per-
formed in PubMed MEDLINE with medical subject headings (MeSH).
In the scientific literature, there are a variety of manuscript types, but in principle, a count
of publications should only include peer-reviewed research papers. Articles and reviews are
normally peer-reviewed, and these were included in our counts. Letters constitute a heteroge-
neous category. They include peer-reviewed short communications, but also un-refereed corre-
spondences. It was not algorithmically possible to distinguish between the two types of letters.
However, we considered it more important to include the peer-reviewed letters than to exclude
non-peer reviewed letters; therefore, we decided to include all letters.
To compare the geographical affiliation of collaborating authors, we retrieved the country-
element of the addresses registered for the authors of each paper. We defined European coun-
tries as the 28 countries of the EU plus Switzerland, Norway, Iceland, Macedonia, and Turkey,
based on their central location in the EU and/or their candidacy to become an EU member
state. We compared papers from the EU to those from the US and those from the Asian conti-
nent, which included Russia. In most cases, these three groups explained close to 100% of the
addresses identified.
We used both the names and addresses of authors from the SCI-E-data. These data were
given in the journal, typically supplied by the authors. Nevertheless, these data may have con-
tained spelling errors, due to a lack of standards or differing standards between journals. We
only used the country information of addresses; therefore, this was a minor issue. All country
information was easily standardised.
Variations and ambiguity in author names were resolved in some systems by canonical or
authorised author names. Although WoS used the so-called ResearcherID, this system was not
fully incorporated in the entire database, nor was the more recent OrcID system available for
cases of retrieval. Thus, cases of two or more authors that used the same name or cases with dif-
ferent spellings of the same name remained problematic. Some attempts have been made to re-
solve these issues [14–16], primarily by using co-author-based clustering techniques. In the
present study we used initial clusters to identify spelling variations of author names combined
with manual searching for the more prominent author names. The disambiguation was per-
formed by one of the authors with no prior knowledge of the field and subsequently evaluated
by the other authors with expert knowledge of this field. While no clustering technique or man-
ual approach will ever produce a completely accurate picture of authorships, our expert evalua-
tion suggests an acceptable margin of error.
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Bibliometric method and mapping
The bibliometric method was based on identifying particularly strong collaborations between
authors, based on the number of co-authored papers [17–19]. Traditionally, maps of author
collaborations are created by first applying similarity matrices, based on the number of co-
authored papers, to construct clusters of authors that work on similar topics [19]. Then, a map-
ping technique was used to illustrate the clusters. We used Pajek64, version 3.15 (http://pajek.
imfm.si/doku.php) for co-author network analysis. For clustering, the Louvain community
clustering method [20] was used, with resolution parameter 1.0 and multi-level coarsening and
refinement. The choice of resolution parameter was based on a combined comparison with hi-
erarchical agglomerative clustering (not shown) and expert prior knowledge about the multiple
myeloma field. As the default resolution parameter of 1.0 provided meaningful clusters in the
multiple myeloma dataset, the same value was also used for the other datasets. For mapping,
the Kamada-Kawai layout was used with internal cluster optimisation, as this layout provided
the most clearly visible structures. The clustering was performed by means of all authors with
at least 20 publications in the entire time frame and all edges were included in all calculations.
For the visual layout however, edges with values below 10 were removed to provide a clearer
image. This has the consequence that some inter-cluster links are not shown. The maps were
also created with VOSviewer version 1.5.5 for comparison, resulting in comparable clusters
and maps (data not shown).
Clusters were evaluated using two measures of cluster density: clustering coefficients for im-
mediate neighbours (CC1) and closeness centrality (Cclose). While both measures express a vari-
ant of density, they differ somewhat in their interpretation. The CC1 indicates for each
member of a network how many other members are in the neighbourhood compared to the
total potential neighbours [21], while the Cclose indicates the average (inverse) shortest distance
from any member of a network to all other members [22]. As both indicators work on entire
graphs, clusters were extracted as subgraphs before calculating these measures in Pajek.
Key indicators of productivity and impact
The productivity and impact of research groups were assessed by numbers of publications
and citations.
1) For publication counts, we measured full and fractional counts [23] to show actual differ-
ences and relative productivity. Comparing publications among clusters depended on:
• Cluster publication counts, Nc, or the full count, was defined as the total number of unique
papers per cluster, where at least one author from the cluster was listed as an author, regard-
less of whether it was first, last, or any other place in the author list.
• Fractional cluster author counts was defined as pfc ¼
XN
i¼1 ni=ai, where ni was the number
of authors from the respective cluster that appeared on a paper i, ai was the total number of au-
thors on paper i, and N was the total number of papers that listed at least one author from
the cluster.
• Intra-cluster collaboration was defined as the ratio pfc/Nc, or the proportion of co-author-
ships within a cluster by authors from that cluster.
2) We used the total citation counts at the date of collection, and standardised these accord-
ing to year of publication. While some impact indicators use field standardisation to compen-
sate for differing citation densities (e.g. [24]), the data used in this paper is from four closely
related subjects, each of which is defined on a more specific level than the WoS subject catego-
ries otherwise available for field standardisation. Thus we consider a publication year
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standardisation sufficient. Standardisation can incorporate several elements, such as log-nor-
malisation, omission of uncited papers or z-scores, however; to provide the most transparent
normalisation, we chose to divide the citations for any paper i, ci, by the mean citations to pa-
pers published the same year and for the same disease category. We denote the normalised cita-
tions for paper i as si and the mean normalised citation score of all papers for a given group
as µs. These mean normalised citation scores should be interpreted with care, especially for
small groups, due to the highly skewed nature of citations [25]. We counted the actual citations
that referred to papers instead of, e.g., the impact factor of the journals in which the papers
were published. This approach achieved a more direct measure of the impact of the individual
papers. It was previously shown that citations to papers in any given journal are highly skewed
[25]. This tendency towards skewness is observed in most bibliometric variables, such as jour-
nals, authors, universities, countries etc. Therefore, the journal impact factor is rarely descrip-
tive of a single paper. It is important to note, that while the citation normalisation approach
described above suffers from the same vulnerability as the journal impact factor, we do not use
it to describe single papers but only for aggregates such as clusters of author, countries and re-
search groups. To further compensate for the skewness of citations, we also use a top-decile in-
dicator, which we denote as PPtop10, inspired by the similar indicator used in the CWTS Leiden
ranking system [24]. For each disease category we find the normalised citation score of the
paper ranking at the top decile limit, sD10. All papers in this disease category with si above this
score are considered top papers, and the PPtop10 indicator can subsequently be calculated for
any set of papers A as PPtop10 = jA \ D10j/jAj, where j.j denotes the cardinality of a given set
and D10 the set of top decile papers. The expected score would be 0.1, with values above indi-
cating higher than expected performance.
A plethora of other metrics exists. However, we believe for comparing the impact of re-
search groups in a given time period for so closely related research areas, the chosen indicators
are the best suited. In particular when the mean- and percentile-based indicators are used to-
gether, as the latter can compensate for potential skewness of the former [24, 26–28].
Data validation and follow up
A comparison between SCI-E and PubMed MEDLINE databases, based on medical subject
headings (MeSH) for publications during the years 2005–09 is given in S1 Table. A large num-
ber of the publications were meeting abstracts registered only in the SCI-E. However, the num-
ber of scientific reports, reviews, and letters registered seemed to increase steadily over time for
multiple myeloma, lymphoma, and leukaemia (S2 Table). For multiple myeloma the relative
increase over time is 42% while it is 22% and 14% respectively for the other diseases, showing a
far greater relative growth in multiple myeloma research.
A follow-up was performed for multiple myeloma specifically, in order to track productivity
and impact over a longer period of time. The dataset was thus broadened to all multiple myelo-
ma papers from 2003–2013. This dataset is analysed separately, as the other diseases were not
analysed over the same period of time, and impact analyses for recent years are somewhat
less stable.
Results
Cluster identification and research output
Collaborative clusters were successfully identified using the Louvain clustering algorithm. Bib-
liometric co-author maps were constructed for multiple myeloma (Fig. 1), lymphoma (S1 Fig.),
and leukaemia (S2 Fig.). We only included authors with> 20 publications during the time pe-
riod indicated. Each map illustrates the collaborating networks; the vertices (or circles)
Bibliometric Mapping and Clustering of Collaborative Research in MM
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illustrate one author, the circle size indicates the number of publications in the given time peri-
od, the thickness of edges between vertices the degree of collaboration, and common colours
show clusters of associated authors. Numbers inside the vertices are IDs of clusters, which in
the following tables are used in combination with disease codes (my = myeloma, le = leukemia
etc) so that my1 is cluster 1 in the multiple myeloma map.
The clusters were analysed for productivity and other descriptive data (Table 1, S3 and
S4 Table). Productivity was reflected by the total number of publications in the cluster (Nc),
and the fractional count of publications per cluster (pfc). It should be noted that the clusters did
not contain all papers in the datasets, as they were generated from authors with at least 20 pub-
lications in the time period. The publication rates differed for multiple myeloma, lymphoma,
and leukaemia, with medians of 211 (range 27–794), 341 (range 20–1164), and 328
(range 19–2649), respectively. While the omission of authors with less than 20 papers leads to a
reduction in the total data, it was necessary to use a threshold in order to allow interpretation
of the maps. The results should thus be seen as representative of the most productive research-
ers rather than the entirety of multiple myeloma research.
Fig 1. Multiple myelomamapping and clustering of authors with>20 publications. These network maps illustrate the collaboration networks of all
authors in the datasets. Each vertex in the map illustrates an author, the size of the vertex indicates the number of papers published by this author, on the
respective subjects in the given time period. The thickness of lines between authors indicates the degree of collaboration between them and the colours
indicate which authors are associated with the same cluster. EU members form the clusters my1, my6, my5, and my7. My1 is the yellow cluster spread over
the majority of the map, while my6 is shown as a white cluster towards the bottom. My5 and my7 are two-person clusters. The majority of EMNmembers are
present in my1, with the exception of H Goldschmidt from GMMG, Germany, in cluster my6. The three most highly cited clusters from the US, my2, my3, and
my4 include the red cluster, which includes KC Anderson from Dana-Farber Cancer Institute (DFCI), Boston, MA, the blue cluster, which includes B Barlogie
from the University of Arkansas Medical Sciences (UAMS), Little Rock, AR, and the green cluster, which includes A Dispenzieri and SV Rajkumar from the
Mayo Clinic in Rochester, MN, Phoenix, AZ, and Jacksonville, FL.
doi:10.1371/journal.pone.0116966.g001
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The intercontinental and worldwide collaborations for each cluster were graded by calculat-
ing the distribution of EU, US, or Asian partners. The most specific collaboration-indicator
was the ratio between the fractional and the full publication counts (pfc/Nc). The closer this
number was to 1, the greater the intra-cluster collaboration; i.e., a larger number of authors on
each publication belonged to the same cluster. Table 1, S3 and S4 Table show that this indicator
(pfc/Nc) for multiple myeloma, lymphoma, and leukaemia had medians of 0.281 (range 0.122–
0.412), 0.256 (range 0.117–1), and 0.258 (range 0.189–1), respectively. The medians for each
disease are comparable, indicating similar strengths in collaborations regardless of disease,
which should be seen in spite of disease-specific differences, such as the relatively lower inci-
dence rate of multiple myeloma. We thus compared the multiple myeloma clusters to acute
myeloid leukaemia (AML) research, another bone marrow disease with the same incidence (S5
Table). We found that the collaboration indicator (pfc/Nc), median 0.195 (range 0.124–0.325),
was somewhat lower for AML, which supports the notion that multiple myeloma research has
closer intra-cluster collaboration than could be expected.
Cluster impact by citations
The impact of publications was indicated by the mean standardised citation score (µs) as shown
in Table 1, S3 and S4 Table. The µs values for multiple myeloma, lymphoma, and leukaemia
were 1.465 (range 0.67–2.06), 1.42 (range 0–2.28), and 1.075 (range 0–2.49), respectively. These
results indicated that the multiple myeloma clusters had a high level of impact. Again, we com-
pared multiple myeloma research with acute myeloid leukaemia research, and found a median
µs = 1.47 (range 0.23–2.17), with highest values for the US clusters (S5 Table). Comparably,
among the multiple myeloma clusters, the US also had higher µs values (2.06, 1.93, and 1.90)
than the identified EU clusters (1.48, 1.45, 1.20 and 0.99) (Table 1). In other words, the high
level of research impact observed in the multiple myeloma clusters depended on the citations
from the US, anchored in clusters my2, my3, and my4. Note that my3 has almost equal EU and
US contributions, but is classified as a US cluster here, as the US is a single contry responsible
for almost half of the addresses present in the cluster, while the EU represents several countries
Key players in multiple myeloma research
An overview of the multiple myeloma-related cluster scores is displayed in Table 1, and the
corresponding co-author map is shown in Fig. 1. Most importantly, compared to the US-based
Table 1. Descriptions of multiple myeloma research clusters ranked by publication counts.
Cluster ID Nc pfc pfc/Nc µs PPtop10 Ccoeff Cclose EU US Asia
my1 794 227.66 0.287 1.48 0.16 0.789 0.384 74.10% 16.10% 1.10%
my2 387 159.32 0.412 1.93 0.23 0.912 0.249 27.60% 51.90% 4.10%
my3 364 147.03 0.404 1.9 0.24 0.851 0.362 44.50% 45.60% 5.40%
my4 327 102.06 0.312 2.06 0.26 0.847 0.446 28.10% 59.30% 4.80%
my6 95 19.4 0.204 1.45 0.11 1 0 83.90% 6.60% 0.50%
my8 40 4.89 0.122 0.67 0.05 0 0 2.40% 0.00% 95.10%
my5 27 7.41 0.275 1.2 0.15 0 0 88.20% 8.80% 2.90%
my7 27 6.19 0.229 0.99 0.11 0 0 80.30% 16.40% 3.30%
Descriptive data for all clusters: Nc = total publication count; pfc = fractional publication count; pfc/Nc = ratio between pfc and Nc, indicating degree of intra-
cluster collaboration; µs = mean standardised citation score; PPtop10 = proportion of publications from the top decile; Ccoeff = 1-neighbourhood cluster
coefﬁcient; Cclose = mean closeness centrality for the cluster; EU, US, Asia = fraction of addresses on papers from the respective areas.
doi:10.1371/journal.pone.0116966.t001
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clusters, the edges inside EU clusters are much smaller, indicating a lower intra-cluster collabo-
ration rate during 2005–2009 (Table 1 and Fig. 1). However, during the interval from 2003 to
2013, the EU clusters move toward each other (Fig. 2, map for 2008–2013); this movement was
most likely a consequence of the EMN collaboration initiated in 2003. This observation is fur-
ther discussed in the time dependent analysis of multiple myeloma research reported below.
Of interest, among the three US clusters, my2 and my3 are institutional members of the
Multiple Myeloma Research Consortium (MMRC), founded in 2004. This consortium brought
together an extraordinary group of US myeloma researchers and world-renowned institutions
Fig 2. Co-author cluster changes from 2003–2007 to 2008–2013. This network diagram illustrates the change in collaborative research over the periods
shown; only authors with more than 20 papers in each period are included. Green circles represent EMNmembers, while the other colours represent the
three major US clusters (my2: yellow, my3: red, my4: blue). The green edges represent inter-EMN collaboration while blue edges represent collaboration
between EMN and non-EMN authors.
doi:10.1371/journal.pone.0116966.g002
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to speed up translational and clinical developments in multiple myeloma. During 2005–2009,
the three US clusters were well defined, with relatively abundant intra-cluster collaborations
(Table 1 and Fig. 1).
Key players in lymphoma and leukaemia research
The lymphoma related cluster scores are given in S3 Table. The highest production and impact
were observed in clusters ly8, ly11, ly6, ly2, and ly1. Researchers from the EU Lymphoma Insti-
tute (ELI) were identified in ly5 and ly7.
The leukaemia related cluster scores are given in S4 Table. One of the three most highly
cited clusters (le4), mainly consists of EU researchers, while the other two are mostly US-based.
Other large clusters from the EU are le7, le16, le12, le3, le8, and le14.
Time dependent development for the multiple myeloma clusters
To analyse the development of the EMN and the three major US-clusters (my2, my3, and my4)
over time, the multiple myeloma dataset was extended from 2003 to 2013, using the same ap-
proach as that used for the main dataset. The cluster density indicators CC1 and closeness cen-
trality are reported in Fig. 3a, along with a collaboration fraction indicator. This final indicator
was only calculated for the EMNmembers and is the ratio between number of publications co-
authored by two or more EMNmembers and those with only one author from the EMN. The
three US clusters are very dense regardless of which indicator is used, while the EMNmembers
do not collaborate as densely, in particular when looking at the closeness centrality. However,
when the networks are plotted for two time periods (2003–2007 and 2008–2013, Fig. 2) the
number of edges between EMNmembers indicates a tighter collaboration, while the weights of
the edges indicates that these collaborations do not occur as frequently as for the US clusters.
This observation is strengthened by the growing collaboration fraction (Fig. 3a) while the clus-
ter densities are stagnant. We interpret this as growing EMN collaboration, but less systemati-
cally than in the US clusters, so that the probability of any two EMNmembers collaborating
grows over time. However, all EMNmembers will rarely collaborate on the same publication,
and they will be more likely to swap collaborators from publication to publication. The growth
in collaboration may have been a consequence of the EMN activities. As it is apparent from
Fig. 3a the cluster densities for the EMNmembers are lower than for the three clusters. It is,
however, obvious that they should be lower, as the clusters are chosen to be dense clusters,
while the EMN group is not a cluster chosen by a density criterion, but a given group of authors
which do not necessarily all collaborate. We therefore compared the EMN group and US clus-
ters to a set of randomly selected groups of authors. The random distribution was generated
from the complete time period, as were the cluster measures for the other aggregates in Fig. 3b.
Thousand random draws of 46 authors with minimum 20 papers. Theoretically, the EMN
group of 46 authors can be drawn from this random sample, which is why we assessed the
probability of getting a group with more extreme cluster behaviour than the EMN group by
random selection. These two-tailed p-values were found from the quantile rank of EMN scores
in the random distributions. For the closeness centrality, EMN scores were above any recorded
values (p = 0.000), and for the clustering coefficient, the EMN scores were in the upper 0.2%
(p = 0.004). This provides evidence that the EMN group collaborates more closely than what
could be expected if they had just been a randomly selected group of authors.
In Fig. 3c and 3d we show the development in citation impact over time for the EMN-
authored publications. Whether using the mean normalised citation rate, µs, or the top-10% frac-
tion, it is clear that publications where EMNmembers collaborate (Multi-EMN) have a higher ci-
tation impact than those where only one of the authors is from the EMN (Single-EMN).
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We analysed the impact of research, according to nationality, by comparing the PPtop10
scores per country for multiple myeloma research (Fig. 4). The results indicated that the re-
search impact in most European countries matches the US level.
Discussion
Before the turn of the millennium, basic and applied research in the field of multiple myeloma
made slow progress. This situation has changed, due to a broadening interest in basic research,
evolving drug designs, and novel therapies in both the EU and US. Until recently, most EU re-
search activities lacked coordination; thus, unlike in the US, very few basic research endeavours
have resulted in major clinical developments or breakthroughs. It was evident that major bene-
fits could be gained from coordination, integration, and harmonization of activities, as sug-
gested by the EU Framework Programmes (FP). Originally, the FP initiated the EMN and
united 12 leading European institutions and national cooperative clinical trial groups, includ-
ing the Haemato Oncology Foundation for Adults in the Netherlands (HOVON; The
Fig 3. Time-dependent progress for the multiple myeloma networks. A: The two cluster density measures are shown for three year intervals (each data
point is calculated from the displayed year and two years ahead to allow networks to form). The collaboration fraction is calculated as the number of papers
with more than one author from the EMN, divided by all papers with at least one author from the EMN. B: the cluster density measures for the entire period are
compared to 1,000 randomly drawn groups of the same size as the EMN group. C: The µs scores per year for the EMN group, when considering all
publications (blue) versus those with only one EMNmember (red) and at least two EMNmembers as authors (green). The shaded areas indicate the.95
confidence intervals. D: Similar to C, but using the PPtop10 indicator.
doi:10.1371/journal.pone.0116966.g003
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Netherlands, Belgium), Central Myeloma Study Group (CEMSG; Austria), Deutsche Studien-
gruppe Multiples Myelom (DSMM; Germany), German Speaking Myeloma Multicenter
Group (GMMG; Germany), Nordic Myeloma Study Group (NMSG; Sweden, Denmark, Nor-
way, Finland, and Iceland), Gruppo Italiano Malattie EMatologiche dell0Adulto (GIMEMA;
Italy), Medical Research Council (MRC; UK), and Programa para el Estudio de la Terapéutica
en Hemopatía Maligna (PETHEMA; Spain). In addition, the network included groups from
Greece, the Czech Republic, Israel, and Turkey. Unfortunately, this network was unsuccessful
in applying for Network of Excellence status and procuring support from the FP6th. Although
most partners have established a range of EMN activities, the question remains as to whether
the EMN collaborative outcome and impact over the last decade have paralleled the improve-
ments in treatment outcome for patients.
The present report aimed to identify scientific collaborations, output, impact, international
key players, and research developments over time by mapping the international research net-
works for multiple myeloma. The analysis of publication productivity and impact identified
several successful groups with a high level of intra-cluster collaboration in the EU and US.
However, US-based research clearly stands out as the most highly cited, even though EU re-
search groups have considerable impact and have shown increased activity over time. These
Fig 4. Proportion of top decile cited papers per country. The proportion of top decile cited papers per country, indicated by green bars. Countries are
ordered by PPtop10.
doi:10.1371/journal.pone.0116966.g004
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findings may guide us in restructuring the EMN organisation and infrastructure to implement
a scientific strategy that focuses on specific areas that have potential impact on translational re-
search, drug development and patient care.
The new era of ‘omics’ information will allow implementation of individual treatment strate-
gies. A range of recent policy initiatives in EU address this issue and accelerate international
projects toward personalized medicine. It is increasingly important to identify individuals who
are unlikely to benefit from current treatment, or are at high risk to develop long-term side ef-
fects and therefore may benefit from novel or selected treatment regimens. This approach, per-
sonalized or precision medicine, is the key to reduction of the burdens of healthcare. Not only
will it improve clinical outcomes, but it will ensure an efficient use of healthcare resources when
fully developed. Personalized medicine includes diagnostics, biomarkers and drug development
making a more complete understanding of the underlying disease mechanisms a prerequisite.
Initiatives that facilitate the adoption of personalized medicine are steadily progressing in Eu-
rope, including European Medicines Agency (EMA) working parties, Innovative Medicines Ini-
tiatives (IMI) and Horizon2020. Personalized medicine will not succeed without grant support
to health care professionals with interest in rare diseases, to ensure benefit for health cost-
effectiveness. EMN represents such an organisation, in urgent need for EU support.
The main infrastructure of the EMN includes the Secretariat, placed in Denmark (Aalborg/
NMSG), the EMN Data and Statistical Centre, placed in Italy (Torino/GIMEMA) and the
Netherlands (Rotterdam/HOVON), the EMN Sponsor Offices in Denmark and the Nether-
lands, the National and Regional Clinical Research Units, and the Network of European Mye-
loma Biobanks and Laboratories. The EMN has been approved by the European Haematology
Association (EHA) as an official scientific working group. The EMN also provides clinical rec-
ommendations and organises major clinical phase II-III trials to be carried out across the EU,
with financial support from pharmaceutical companies. From unrestricted grants to the orga-
nization, the EMN has supported and facilitated the advent of the Myeloma Stem Cell Network
(MSCNET), the translational project on Resistance and Targeted Therapy (RESTART), the
Clinical Trial Network (TALISMMAN), and the MyelomA Genetics International Consortium
(MAGIC).
The results from this analysis are retrospective and indicative in nature. However, the most
significant observation was the intercontinental difference between the EU and US in outcome
and impact. We observed indications that the major performance group in multiple myeloma
research, my3, includes awardees of the 2.7 million USD SPORE Grant [29] and collaborations
with researchers from one of the other US-groups, my4. The other US-based research group,
my2, is supported by a 3 million USD grant from the US NCI [30]. The NCI investment in
multiple myeloma research has increased steadily, from $41.5 million in 2008 to $61.3 million
in 2012. In addition to that investment, the NCI invested $5.6 million to support multiple mye-
loma research in 2009 and 2010 with funding from the American Recovery and Reinvestment
Act [31].
There are no differences between the EU and US in the incidence and prevalence of multiple
myeloma. It has been estimated that more than 20,000 individuals will be diagnosed with mul-
tiple myeloma in the US and in the EU during 2014, and more than 10,000 patients will die an-
nually as a result of resistant disease. Although we cannot draw any direct conclusions from
our analyses, it may not be surprising that well-funded, collaborative, focused research projects
produce intra-cluster collaborative progress and high-impact research papers. The EU invest-
ment in multiple myeloma research is unknown, but the EMN partnership has estimated that
the investment is far below the US level.
We conclude that the fragmented European multiple myeloma research activities performed
by national or regional groups are progressing towards international collaborations. Therefore,
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our findings can provide the basis for an updated EMN strategy for achieving the content and
output expected from future multiple myeloma research. This strategy should be decided by
the EMN board and leading partners from the Myeloma Biology and Clinical Trial Groups. A
clearly defined “top down” strategy for EMN will give all members a precise description of the
achievements needed to apply successfully for Horizon 2020 grant support.
Supporting Information
S1 Fig. Lymphoma mapping and clustering of authors with> 20 publications. This network
maps illustrate the collaboration networks of all authors in the datasets. Each vertex on the
map illustrates an author, the size of the vertex indicates the number of papers published by
this author, on the respective subjects (S3 Table), in the given time period. The thickness of
lines between authors indicates the degree of collaboration between them and the colours indi-
cate which authors are associated with the same cluster.
(TIF)
S2 Fig. Leukaemia mapping and clustering of authors with> 20 publications. This network
maps illustrate the collaboration networks of all authors in the datasets. Each vertex on the
map illustrates an author, the size of the vertex indicates the number of papers published by
this author, on the respective subjects (S4 Table), in the given time period. The thickness of
lines between authors indicates the degree of collaboration between them and the colours indi-
cate which authors are associated with the same cluster.
(TIF)
S3 Fig. Acute myeloid leukaemia mapping and clustering of authors with 10 or more pa-
pers. This network maps illustrate the collaboration networks of all authors in the datasets.
Each vertex on the map illustrates an author, the size of the vertex indicates the number of pa-
pers published by this author, on the respective subjects (S5 Table), in the given time period.
The thickness of lines between authors indicates the degree of collaboration between them and
the colours indicate which authors are associated with the same cluster.
(TIF)
S1 Table. Search results compared betweenWeb of Science and PubMed.Queries for multi-
ple myeloma, lymphoma, and leukaemia in Science Citation Index-Expanded (SCI-E) and
PubMed MEDLINE, delimited to publication years = 2005–2009. The refined SCI-E query
contains only articles, reviews, and letters.
(PDF)
S2 Table. Counts of papers over time. Publication counts in SCI-E distributed by
publication year.
(PDF)
S3 Table. Descriptions of lymphoma research clusters ranked by publication counts. De-
scriptive data for all clusters: Nc = total publication count; pfc = fractional publication count;
pfc/Nc = ratio between pfc and Nc, indicating degree of intra-cluster collaboration; µs = mean
standardised citation score; PPtop10 = proportion of publications from the top decile; Ccoeff =
1-neighbourhood cluster coefficient; Cclose = mean closeness centrality for the cluster; EU, US,
Asia = fraction of addresses on papers from the respective areas.
(PDF)
S4 Table. Descriptions of leukaemia clusters ranked by publication counts. Descriptive data
for all clusters: Nc = total publication count; pfc = fractional publication count; pfc/Nc = ratio
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between pfc and Nc, indicating degree of intra-cluster collaboration; µs = mean standardised ci-
tation score; PPtop10 = proportion of publications from the top decile; Ccoeff = 1-neighbourhood
cluster coefficient; Cclose = mean closeness centrality for the cluster; EU, US, Asia = fraction of
addresses on papers from the respective areas.
(PDF)
S5 Table. Descriptions of acute myeloid leukaemia clusters ranked by publication counts.
Descriptive data for all clusters: Nc = total publication count; pfc = fractional publication count;
pfc/Nc = ratio between pfc and Nc, indicating degree of intra-cluster collaboration; µs = mean
standardised citation score; PPtop10 = proportion of publications from the top decile; Ccoeff =
1-neighbourhood cluster coefficient; Cclose = mean closeness centrality for the cluster; EU, US,
Asia = fraction of addresses on papers from the respective areas.
(PDF)
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